Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Rudwaleit, Martin ^a   Van den Bosch, Filip ^b   Kron, Martina ^c   Kary, Sonja ^c   Kupper, Hartmut ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADD ON THERAPY; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PSORIATIC ARTHRITIS; TREATMENT RESPONSE; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953505954     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3054     Document Type: Article

References (38)

1. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2008, 69 Suppl 1:i2-i29. 10.1136/ard.2009.123885, 19995740.
2. Gomez-Reino JJ, Carmona L, . BIOBADASER Group Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006, 8:R29. 10.1186/ar1881, 1526564, 16507128, BIOBADASER Group.
3. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007, 66:1393-1397. 10.1136/ard.2007.073569, 17613555.
4. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor α agent in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:13-20. 10.1002/art.22331, 17195186.
5. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007, 46:1191-1199. 10.1093/rheumatology/kem091, 17504821.
6. Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, Drosos AA. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006, 65:257-260. 10.1136/ard.2005.039099, 1798023, 15975964.
7. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:795-800.
8. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa; data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003, 62:1195-1198. 10.1136/ard.2003.009589, 1754380, 14644858.
9. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004, 22:S115-S121.
10. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor-α antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology 2006, 45:1121-1124. 10.1093/rheumatology/kel054, 16510526.
11. Delaunay C, Farrenq V, Marini PA, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005, 32:2183-2185.
12. Cantini F, Niccoli L, Benucci M, Chindamo D, Nannini C, Olivieri I, Padula A, Salvarani C. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006, 55:812-816. 10.1002/art.22236, 17013842.
13. Coates LC, Cawkwell LS, Ng NWF, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 2008, 47:897-900. 10.1093/rheumatology/ken094, 18403400.
14. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008, 67:717-719. 10.1136/ard.2007.082925, 18055476.
15. Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C. Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology 2008, 47:1726-1727. 10.1093/rheumatology/ken334, 18782856.
16. Arends S, Brouwer E, van der Veer E, Kallenberg CG, Jansen TL, Houtman PM, Spoorenberg A. Effect of switching between infliximab, etanercept and adalimumab in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:624.
17. Abbott Laboratories HUMIRA: package insert. 2009, Abbott Park, IL, Abbott Laboratories.
18. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36:801-808. 10.3899/jrheum.081048, 19273449.
19. Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, van Vollenhoven RF, Leirisalo-Repo M, FitzGerald O, Kron M, Frank M, Kary S, Kupper H. Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions. Ann Rheum Dis 2010, 69:394-399.
20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368. 10.1002/art.1780270401, 6231933.
21. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
22. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886. 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F, 11508441.
23. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:316-320. 10.1136/ard.2005.040758, 1798064, 16096329.
24. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
25. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, Tempel H, Mielants H, Dougados M, van der Heijde D. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62:127-132. 10.1136/ard.62.2.127, 1754445, 12525381.
26. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR J, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39:2013-2020. 10.1002/art.1780391210, 8961906.
27. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735. 10.1002/art.1780380602, 7779114.
28. Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995, 22:886-893.
29. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24-35. 10.1002/art.11417, 14730596.
30. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003, 49:206-212. 10.1067/S0190-9622(03)00910-1, 12894066.
31. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J, , Braun J. 'ASsessment in AS' international working group, European League Against Rheumatism ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 56:442-452. 10.1136/ard.2005.041137, 16126791, 'ASsessment in AS' international working group, European League Against Rheumatism.
32. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ, . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68:1387-1394. 10.1136/ard.2008.094946, 2719080, 18952643, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
33. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, . ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146. 10.1002/art.21913, 16802350, ATLAS Study Group.
34. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, . Adalimumab effectiveness in psoriatic Arthritis Trial Study Group Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289. 10.1002/art.21306, 16200601, Adalimumab effectiveness in psoriatic Arthritis Trial Study Group.
35. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004, 63:1594-1600. 10.1136/ard.2004.020875, 1754832, 15345498.
36. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390. 10.1016/S0140-6736(00)02530-7, 10972371.
37. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, . Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 582-591. 10.1002/art.20852, 15692973, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
38. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005, 1227-1236. 10.1002/art.20967, 15818699.